Drug Candidate Marketplace
Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs and download the list. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. Additional information will be provided to you.
| Date | Candidate | Mechanism of action | Indication | Route | Modality | Development stage | Note | |
|---|---|---|---|---|---|---|---|---|
| 04/02/19 | GEM071 | Nanoparticl formulation of 2-deoxy-glucose | Hepatocellular carcinoma, Renal cancer, Colorectal canser | IV | Small molecule |
Preclinical | In the xenograft model, the administration of nanoparticle formulation once a week showed superior antitumor effect than daily administration of 2-deoxyglucose alone. No side effects were observed. Enhanced the antitumor effect by combination with existing anticancer drugs. Enhanced T cell infiltration into tumor tissue. The substrate used in the nanoparticle formulation are used in approved medicines (FDA). |
Contact |
| 04/02/19 | GEM070 | Nanoparticl formulation of ɤ- Oryzanol | Diabetes, hyperlipidemia, menopausal disorder, irritable bowel syndrome, etc. | Oral | Small molecule |
Preclinical | Improved intestinal absorption and shows a drug effect in an extremely small amount (1/1000 of normal particles). Reduced preference for high fat diet. Suppressed ER stress enhancement on hypothalamic/pancreatic islet. Improved abnormal glucose metabolism and abnormal lipid metabolism. The substrate used in the nanoparticle formulation are used in approved medicines (FDA). |
Contact |
| 03/12/19 | GEM024 | 1. Selective inducer of apoptosis through modulation of NF-kB/P53 axis. / 2. Eliciting adaptive immune response by recruitment of T Cells to tumors. | Oral Squamous Cell Carcinoma | see Note | Small molecules |
Phase 2 ready | Updated on March 12, 2019 First-in-class, patented, combination therapeutic that simultaneously upregulates a cluster of genes promoting cell death and downregulates a cluster of genes promoting survival of cancer cells. Phase 1 results showed no significant AE, dose-dependent modulation of key biomarkers involved in disease pathogenesis, and T cell recruitment to tumor making it “hot”. FDA approved moving to Phase 2. Route:Oral, pastille based topical delivery |
Contact |
| 03/07/19 | GEM069 | Immuno-modulator (adjuvant) | Vaccine, Please refer to Note | Injection | Others |
Preclinical | E.coli producing monophosphoryl Lipid A whose structure is similar to exsiting adjuvants such as MPL and GLA. Shows similar efficacy with MPL in vitro and in vivo. Lower cost production through simple fermetation and purification steps. Indication:Vaccine, Cancer immunotherapy etc. |
Contact |
| 03/01/19 | GEM068 | Gene therapy for novel target | Lung and other cancers | IV | Nucleic acids |
Preclinical | The expression of this gene is reduced in various cancers. Adenovirus expressing this gene inhibits the HIF-1α expression and proliferation of various cancer cells. Adenovirus expressing this gene suppresses growth of lung cancer in nude mice. |
Contact |
| 03/01/19 | GEM067 | c-Kit inhibitor | Diabetic macular edema & Retinopathy | Oral | Small molecules |
Phase 2a | Inhibits stem cell factor-induced hyperpermeability Reverses retinal vascular leakage in STZ-induced diabetic rats Improved compliance to administration (oral) than anti-VEGF therapy (intra-vitreal injection) Applicable to non-responders to anti-VEGF therapy Repositioning of a marketed drug |
Contact |
| 03/01/19 | GEM066 | Selective STAT3 inhibitor (DNA-based Decoy) | Head and neck squamous cell carcinoma and non-small cell lung cancer [including exon 20 mutations] | IV | Nucleic acids |
Pre-IND for systemic administration formulation | 1st-in-class STAT3 decoy; Suppresses binding of STAT3 to genomic DNA; Inhibits proliferation and promotes apoptosis of many cancer cells; Suppresses expression of STAT3 target genes and tumor growth in animal models; Shows increased response in combination with cetuximab and also with PD-1; Human Phase 0 study (intratumor injection); Suppresses STAT3 target genes expression with one dose Does not affect normal oral keratinocytes; Exploratory animal toxicology studies show no significant adverse effects; |
Contact |
| 03/01/19 | GEM064 | Selective inhibitor of Nav channels | Pain | Oral | Small molecule |
Preclinical | Potent and selective inhibitors for Nav 1.7/1.8 subtypes Effective in inflammatory & neuropathic pain states Exellent non-clinical ADMET profile No off-target activity, very good in vitro cardiac safety margin, non-mutagenic |
Contact |
| 02/12/19 | GEM063 | Novel 24hr ibuprofen patch | Local pain in sprains | Local | Small molecule |
Phase 1 completed | High payload: Contains 200 mg ibuprofen, Constant delivery over 24 hours, Class-leading adhesion, Water-resistant, Comfortable to wear and remove Pre-clinical safety studies were completed 2017 with no concerns/issues Phase I PK and sensitisation/irritancy studies were successfully completed in 2018 with no concerns/issues |
Contact |
| 01/11/19 | GEM009 | BET inhibitor | Cancer, RA | Oral | Small molecules |
Preclinical | Updated on January 11, 2019 More potent enzyme inhibition and anti-tumor activities compared with competitors (more potent than GSK525762A and comparble to ABBV-075). Superior safety profile than competitors (no inhibition on hERG or CYP3A4) and can be applied to RA. Easier manufacturing due to absence of asymmetric carbon. |
Contact |